Prognosis and safety of radium‐223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration‐resistant prostate cancer: Real‐world data of Japanese patients

OBJECTIVES: To evaluate the real‐world data on the efficacy and safety of a combination therapy with radium‐223 (Ra‐223) and second‐generation androgen‐receptor targeting agents (ARTAs), including abiraterone acetate (ABI) and enzalutamide (ENZ), among Japanese patients with bone metastatic castrati...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyoshi, Yasuhide, Yasui, Masato, Ttsutsumi, Sohgo, Kawahara, Takashi, Uemura, Ko‐ichi, Hayashi, Naruhiko, Nozawa, Masahiro, Yoshimura, Kazuhiro, Uemura, Hiroji, Uemura, Hirotsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988769/
https://www.ncbi.nlm.nih.gov/pubmed/35474660
http://dx.doi.org/10.1002/bco2.42

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988769/
https://www.ncbi.nlm.nih.gov/pubmed/35474660
http://dx.doi.org/10.1002/bco2.42

Ejemplares similares